Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Boston Scientific (BSX) Gets a Buy from RBC Capital

Tipranks - Tipranks - Sat Mar 28, 12:32AM CDT

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Boston Scientific on March 25 and set a price target of $115.00. The company’s shares closed yesterday at $69.78.

Claim 30% Off TipRanks Premium

According to TipRanks, Singh Chadha is a 3-star analyst with an average return of 0.8% and a 45.77% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Boston Scientific, Inspire Medical Systems, and Becton Dickinson.

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $106.00, a 51.91% upside from current levels. In a report released yesterday, Goldman Sachs also maintained a Buy rating on the stock with a $93.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Boston Scientific’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.29 billion and a net profit of $668 million. In comparison, last year the company earned a revenue of $4.56 billion and had a net profit of $566 million

Read More on BSX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).